In the present study, we first investigated fascin immunoreactivity in NSCLC, comparing two different commercially available monoclonal antibodies in a retrospective series of 220 chemotherapy-naive patients with stage I disease. This evidence concerns the gene FSCN1 and non-small cell lung carcinoma.